The evolving role of Hospital Oncology Pharmacists (HOPs) in assessing therapeutic innovations and managing toxicities in cancer care.

Annales pharmaceutiques francaises Pub Date : 2025-10-08 DOI:10.1016/j.pharma.2025.10.001

Florence Ranchon, Florian Slimano, Maha Ayyoub, Charlotte Bérard, Anaïs Grand, Marie Kroemer, Xavier Paoletti, Vérane Schwiertz, Pascale Tomasini, Christophe Bardin, Emmanuel Raffoux, Catherine Rioufol, Régine Chevrier, Bertrand Pourroy, Jean-Louis Cazin

{"title":"The evolving role of Hospital Oncology Pharmacists (HOPs) in assessing therapeutic innovations and managing toxicities in cancer care.","authors":"Florence Ranchon, Florian Slimano, Maha Ayyoub, Charlotte Bérard, Anaïs Grand, Marie Kroemer, Xavier Paoletti, Vérane Schwiertz, Pascale Tomasini, Christophe Bardin, Emmanuel Raffoux, Catherine Rioufol, Régine Chevrier, Bertrand Pourroy, Jean-Louis Cazin","doi":"10.1016/j.pharma.2025.10.001","DOIUrl":null,"url":null,"abstract":"<p><p>Hospital oncology pharmacy (HOP) is evolving in tandem with the rapid pace of oncology research, encompassing breakthroughs in anticancer therapies, the management of treatment-related toxicities, and the application of novel methodologies for evaluating therapeutic strategies. This paper presents a synthesis on these topics, based in part, on the latest scientific event organized by the French Society for Oncology Pharmacy (SFPO), known as St. Louis' Day. During this event, seven leading experts-comprising medical oncologists and HOPs-engaged in in-depth discussions on three pivotal themes: the assessment of therapeutic innovations, recent progress in cancer-related vaccinology, and the management of immune-related adverse events. The proceedings underscore the critical role of HOPs as key members of the interdisciplinary oncology team, driving ongoing advancements in the quality and safety of cancer care.</p>","PeriodicalId":521031,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales pharmaceutiques francaises","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.pharma.2025.10.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Hospital oncology pharmacy (HOP) is evolving in tandem with the rapid pace of oncology research, encompassing breakthroughs in anticancer therapies, the management of treatment-related toxicities, and the application of novel methodologies for evaluating therapeutic strategies. This paper presents a synthesis on these topics, based in part, on the latest scientific event organized by the French Society for Oncology Pharmacy (SFPO), known as St. Louis' Day. During this event, seven leading experts-comprising medical oncologists and HOPs-engaged in in-depth discussions on three pivotal themes: the assessment of therapeutic innovations, recent progress in cancer-related vaccinology, and the management of immune-related adverse events. The proceedings underscore the critical role of HOPs as key members of the interdisciplinary oncology team, driving ongoing advancements in the quality and safety of cancer care.

查看原文本刊更多论文

医院肿瘤药剂师（HOPs）在评估癌症治疗创新和管理毒性方面的作用。

医院肿瘤药学（HOP）随着肿瘤研究的快速发展而发展，包括抗癌治疗的突破、治疗相关毒性的管理以及评估治疗策略的新方法的应用。本文对这些主题进行了综合，部分基于法国肿瘤药学学会（SFPO）组织的最新科学活动，即圣路易斯日。在本次会议期间，包括医学肿瘤学家和hops在内的七位主要专家就三个关键主题进行了深入讨论：治疗创新的评估、癌症相关疫苗学的最新进展以及免疫相关不良事件的管理。会议强调了HOPs作为跨学科肿瘤学团队的关键成员的关键作用，推动了癌症治疗质量和安全性的持续进步。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annales pharmaceutiques francaises

自引率

0.00%

发文量